Vincenzo Liso

TL;DR: The conclusions are that omission of nonanthracycline drugs from the AIDA regimen is not associated with reduced antileukemic efficacy and a simple predictive model may be used for risk-adapted therapy in this disease.

TL;DR: This study indicates that the AIDA protocol is a well-tolerated regimen that induces molecular remission in almost all patients with PML/RARα-positive APL and suggests that a remarkable cure rate can be obtained with this treatment.

TL;DR: It is concluded that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.

TL;DR: Intention-to-treat analysis revealed that the 4-year disease-free survival (DFS) rate of patients with a donor versus those without a donor was 52.2% versus 42.2%, and the strategy to perform early allo-SCT led to better overall results than auto-S CT, especially for younger patients or those with bad/very bad risk cytogenetics.

TL;DR: In this paper, the authors used morphologic, cytogenetic, and molecular analyses for optimal management of acute promyelocytic leukemia (APL) patients and better understanding of the pathogenesis of the disease.